Quadrant Capital Group’s SpringWorks Therapeutics SWTX Stock Holding History

Quadrant Capital Group’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-100	Closed	-$3.61K	–	2839
2024 Q4	$3.61K	Buy	+100	New	+$3.49K	﹤0.01%	2382
2024 Q2	–	Sell	-23	Closed	-$1.13K	–	2765
2024 Q1	$1.13K	Buy	+23	New	+$1.06K	﹤0.01%	2578
2023 Q4	–	Sell	-52	Closed	-$1.2K	–	2782
2023 Q3	$1.2K	Hold	52	–	–	﹤0.01%	2464
2023 Q2	$1.36K	Hold	52	–	–	﹤0.01%	2471
2023 Q1	$1.34K	Hold	52	–	–	﹤0.01%	2498
2022 Q4	$1.35K	Sell	52 -17	-25%	-$419	﹤0.01%	2489
2022 Q3	$2K	Sell	69 -95	-58%	-$2.72K	﹤0.01%	2428
2022 Q2	$4K	Buy	+164	New	+$6K	﹤0.01%	2057

Other funds holding SWTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Quadrant Capital Group's SWTX Position: Q1 2025 in Review

Quadrant Capital Group sold out of SpringWorks Therapeutics (SWTX) in Q1 2025, closing a stake of 100 shares — an estimated $3.61K sold.

Quadrant Capital Group first reported a position in SWTX in Q2 2022 and held it in 8 quarters. The position peaked at $4K in Q2 2022. 306 funds tracked by Wall St. Rank hold SWTX as of Q1 2025.

Quadrant Capital Group reported no remaining SpringWorks Therapeutics position as of Q1 2025 after selling out during the quarter.
Quadrant Capital Group sold 100 SpringWorks Therapeutics shares in Q1 2025, an estimated $3.61K.
Quadrant Capital Group first reported a position in SpringWorks Therapeutics in Q2 2022 and held it in 8 quarters.
Quadrant Capital Group's SpringWorks Therapeutics position peaked at $4K in Q2 2022.
306 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2025.

Based on Quadrant Capital Group's 13F filing for Q1 2025, filed 13 May 2025.